{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T14:39:15Z","timestamp":1768401555072,"version":"3.49.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.exer.2016.03.021","type":"journal-article","created":{"date-parts":[[2016,3,26]],"date-time":"2016-03-26T15:58:33Z","timestamp":1459007913000},"page":"224-232","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model"],"prefix":"10.1016","volume":"146","author":[{"given":"Ruti","family":"Sella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orly","family":"Gal-Or","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eitan","family":"Livny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mor","family":"Dachbash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Nisgav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dov","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1279-2557","authenticated-orcid":false,"given":"Tami","family":"Livnat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irit","family":"Bahar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2016.03.021_bib1","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00126839-200809040-00006","article-title":"Aflibercept: AVE 0005, AVE 005, AVE0005, VEGF Trap - Regeneron, VEGF Trap (R1R2), VEGF Trap-Eye","volume":"9","year":"2008","journal-title":"Drugs R. D."},{"key":"10.1016\/j.exer.2016.03.021_bib2","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3109\/02713680903429007","article-title":"Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model","volume":"35","author":"Avisar","year":"2010","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2016.03.021_bib3","first-page":"264","article-title":"Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)","volume":"104","author":"Azar","year":"2006","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"10.1016\/j.exer.2016.03.021_bib4","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/bjo.2008.145128","article-title":"Transient postoperative vascular endothelial growth factor (VEGF)-neutralisation improves graft survival in corneas with partly regressed inflammatory neovascularisation","volume":"93","author":"Bachmann","year":"2009","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib5","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/ICO.0b013e318159019f","article-title":"Subconjunctival bevacizumab injection for corneal neovascularization","volume":"27","author":"Bahar","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2016.03.021_bib6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1167\/iovs.06-0570","article-title":"Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis","volume":"48","author":"Bock","year":"2007","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib7","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1167\/iovs.07-1129","article-title":"Safety profile of topical VEGF neutralization at the cornea","volume":"50","author":"Bock","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib8","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1167\/iovs.09-4956","article-title":"A\u00a0subretinal matrigel rat choroidal neovascularization (CNV) model and inhibition of CNV and associated inflammation and fibrosis by VEGF trap","volume":"51","author":"Cao","year":"2010","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.survophthal.2012.01.007","article-title":"Corneal neovascularization: an anti-VEGF therapy review","volume":"57","author":"Chang","year":"2012","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib10","first-page":"404","article-title":"Effects of amniotic membrane suspension in the rat alkali burn model","volume":"17","author":"Choi","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2016.03.021_bib11","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.2146\/ajhp130143","article-title":"Ziv-aflibercept: a novel angiogenesis inhibitor for the treatment of metastatic colorectal cancer","volume":"70","author":"Chung","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.exer.2016.03.021_bib12","first-page":"2666","article-title":"Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival","volume":"45","author":"Cursiefen","year":"2004","journal-title":"IOVS"},{"key":"10.1016\/j.exer.2016.03.021_bib13","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1172\/JCI20465","article-title":"VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment","volume":"113","author":"Cursiefen","year":"2004","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.exer.2016.03.021_bib14","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1001\/archophthalmol.2009.18","article-title":"Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study","volume":"127","author":"Dastjerdi","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib15","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1167\/iovs.11-7871","article-title":"Corneal penetration of topical and subconjunctival bevacizumab","volume":"52","author":"Dastjerdi","year":"2011","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib16","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/archopht.125.6.834","article-title":"Topical bevacizumab therapy for corneal neovascularization","volume":"125","author":"DeStafeno","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib17","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1517\/13543780903201684","article-title":"VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration","volume":"18","author":"Dixon","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.exer.2016.03.021_bib18","first-page":"2326","article-title":"Effect of subconjuctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization","volume":"15","author":"Dratviman-Storobinsky","year":"2009","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2016.03.021_bib19","first-page":"1112","article-title":"Correlation of VEGF expression by leukocytes with the growth and regression of blood vessels in the rat cornea","volume":"40","author":"Edelman","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib20","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1345\/aph.1R705","article-title":"Aflibercept: newly approved for the treatment of macular edema following central retinal vein occlusion","volume":"47","author":"Evoy","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.exer.2016.03.021_bib21","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/ICO.0b013e3182775f8d","article-title":"Topical ranibizumab as a treatment of corneal neovascularization","volume":"32","author":"Ferrari","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2016.03.021_bib22","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/IAE.0000000000000398","article-title":"Frequency and characteristics of intraocular inflammation after aflibercept injection","volume":"35","author":"Fine","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.exer.2016.03.021_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4103\/0301-4738.30702","article-title":"Evaluation of 19 cases of inadvertent globe perforation due to periocular injections","volume":"55","author":"Gadkari","year":"2007","journal-title":"Indian J. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3928\/15428877-20100215-07","article-title":"Corneal melt while using topical bevacizumab eye drops","author":"Galor","year":"2010","journal-title":"Ophthalmic Surg. Lasers Imaging"},{"key":"10.1016\/j.exer.2016.03.021_bib25","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1755-3768.2009.01571.x","article-title":"The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization","volume":"88","author":"Habot-Wilner","year":"2010","journal-title":"Acta. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib26","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000322061","article-title":"Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats","volume":"46","author":"Hashemian","year":"2011","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2016.03.021_bib27","doi-asserted-by":"crossref","first-page":"11393","DOI":"10.1073\/pnas.172398299","article-title":"VEGF-Trap: a VEGF blocker with potent antitumor effects","volume":"99","author":"Holash","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.exer.2016.03.021_bib28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1023\/A:1006486207583","article-title":"Electrocardiographic changes during subconjunctival injections","volume":"23","author":"Kayik\u00e7ioglu","year":"1999","journal-title":"Int. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib29","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2016.03.021_bib30","doi-asserted-by":"crossref","first-page":"4653","DOI":"10.1167\/iovs.08-2805","article-title":"Bevacizumab application delays epithelial healing in rabbit cornea","volume":"50","author":"Kim","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib31","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s00417-009-1099-1","article-title":"Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization","volume":"247","author":"Koenig","year":"2009","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000351627","article-title":"Effect of erythropoietin on healing of corneal epithelial defects in rabbits","volume":"50","author":"Livny","year":"2013","journal-title":"Ophthalmic Res."},{"key":"10.1016\/j.exer.2016.03.021_bib33","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3109\/02713688508999984","article-title":"Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea","volume":"4","author":"Mahoney","year":"1985","journal-title":"Curr. Eye Res."},{"issue":"Suppl.\u00a01","key":"10.1016\/j.exer.2016.03.021_bib34","doi-asserted-by":"crossref","first-page":"i11","DOI":"10.1136\/bjophthalmol-2014-305302","article-title":"Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture","volume":"98","author":"Malik","year":"2014","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib35","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1136\/bjo.2006.107912","article-title":"Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin)","volume":"91","author":"Manzano","year":"2007","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/eye.2011.246","article-title":"Emerging techniques to treat corneal neovascularisation","volume":"26","author":"Menzel-Severing","year":"2012","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.exer.2016.03.021_bib37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s00417-013-2495-0","article-title":"Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes","volume":"252","author":"Moisseiev","year":"2014","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib38","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1167\/iovs.08-3148","article-title":"Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits","volume":"50","author":"Nomoto","year":"2009","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib39","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/02713680802607740","article-title":"The anti-inflammatory effect of subconjunctival bevacizumab on chemically burned rat corneas","volume":"34","author":"Oh","year":"2009","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2016.03.021_bib40","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/112067211002000106","article-title":"VEGF Trap(R1R2) suppresses experimental corneal angiogenesis","volume":"20","author":"Oliveira","year":"2010","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib41","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000337139","article-title":"Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model","volume":"48","author":"\u00d6ner","year":"2012","journal-title":"Ophthalmic. Res."},{"key":"10.1016\/j.exer.2016.03.021_bib42","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/ICO.0b013e3182542613","article-title":"Vascular endothelial growth factor inhibitors for treatment of corneal neovascularization: a meta-analysis","volume":"32","author":"Papathanassiou","year":"2013","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2016.03.021_bib43","first-page":"1","article-title":"Inhibitory effect of topical aflibercept on corneal neovascularization in rabbits","volume":"0","author":"Park","year":"2015","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2016.03.021_bib44","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1038\/eye.2008.88","article-title":"Anti-VEGF therapy: comparison of current and future agents","volume":"22","author":"Pieramici","year":"2008","journal-title":"Eye (Lond.)"},{"key":"10.1016\/j.exer.2016.03.021_bib45","first-page":"104","article-title":"Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes","volume":"17","author":"Rocher","year":"2011","journal-title":"Mol. Vis."},{"key":"10.1016\/j.exer.2016.03.021_bib46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.2147\/DDDT.S40215","article-title":"Aflibercept in wet AMD: specific role and optimal use","volume":"7","author":"Semeraro","year":"2013","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.exer.2016.03.021_bib47","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2147\/OPTH.S33372","article-title":"Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept","volume":"6","author":"Stewart","year":"2012","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib48","doi-asserted-by":"crossref","first-page":"138","DOI":"10.3109\/15569527.2013.813030","article-title":"Topical and subconjunctival ranibizumab (lucentis) for corneal neovascularization in experimental rat model","volume":"33","author":"T\u00fcrkc\u00fc","year":"2014","journal-title":"Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.exer.2016.03.021_bib49","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/ICO.0b013e318158f6ad","article-title":"Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome","volume":"27","author":"Uy","year":"2008","journal-title":"Cornea"},{"key":"10.1016\/j.exer.2016.03.021_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4137\/CMO.S7432","article-title":"Aflibercept in the treatment of metastatic colorectal cancer","volume":"6","author":"Wang","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"key":"10.1016\/j.exer.2016.03.021_bib51","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S1350-9462(01)00008-8","article-title":"The corneal wound healing response: cytokine-mediated interaction of the epitheliu, stroma, and inflammatory cells","volume":"20","author":"Wilson","year":"2001","journal-title":"Prog. Retin Eye Res."},{"key":"10.1016\/j.exer.2016.03.021_bib52","doi-asserted-by":"crossref","first-page":"e30842","DOI":"10.1371\/journal.pone.0030842","article-title":"Role of mesencymal stem cells on cornea wound healing induced by acute alkali burn","volume":"7","author":"Yao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2016.03.021_bib53","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1600-0420.2007.01049.x","article-title":"Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn","volume":"86","author":"Yoeruek","year":"2008","journal-title":"Acta. Ophthalmol."},{"key":"10.1016\/j.exer.2016.03.021_bib54","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1167\/iovs.07-1175","article-title":"Interaction between bevacizumab and murine VEGF-A: a reassessment","volume":"49","author":"Yu","year":"2008","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2016.03.021_bib55","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.2147\/DDDT.S87920","article-title":"Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application","volume":"9","author":"Zhang","year":"2015","journal-title":"Drug Des. Develop. Ther."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483516300513?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483516300513?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:59:13Z","timestamp":1757998753000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483516300513"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":55,"alternative-id":["S0014483516300513"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2016.03.021","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of topical aflibercept versus topical bevacizumab for the prevention of corneal neovascularization in a rat model","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2016.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}